Medifast (MED) Tops Q1 EPS by 3c, Offers Guidance

Medifast (NYSE: MED) reported Q1 EPS of $3.59, $0.03 better than the analyst estimate of $3.56. Revenue for the quarter came in at $417.6 million versus the consensus estimate of $402.42 million.

GUIDANCE:

Medifast sees FY2022 EPS of $14.60-$16.05, versus the consensus of $15.62. Medifast sees FY2022 revenue of $1.78-1.84 billion, versus the consensus of $1.77 billion.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs